Clinical experience with pegaptanib sodium

Chiara Rosina, Ferdinando Bottoni, Giovanni StaurenghiLuigi Sacco Hospital, University of Milano, ItalyAbstract: Pegaptanib sodium (Macugen&reg;) blocks the extracellular vascular endothelial growth factor (VEGF) isoform VEGF165, whose elevated levels are associated with the development of c...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Chiara Rosina, Ferdinando Bottoni, Giovanni Staurenghi
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2008
Materias:	Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/9a2fea8920124e42b8807847999e82d5
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:9a2fea8920124e42b8807847999e82d5
record_format	dspace
spelling	oai:doaj.org-article:9a2fea8920124e42b8807847999e82d52021-12-02T08:49:38ZClinical experience with pegaptanib sodium1177-54671177-5483https://doaj.org/article/9a2fea8920124e42b8807847999e82d52008-10-01T00:00:00Zhttp://www.dovepress.com/clinical-experience-with-pegaptanib-sodium-a2353https://doaj.org/toc/1177-5467https://doaj.org/toc/1177-5483Chiara Rosina, Ferdinando Bottoni, Giovanni StaurenghiLuigi Sacco Hospital, University of Milano, ItalyAbstract: Pegaptanib sodium (Macugen&reg;) blocks the extracellular vascular endothelial growth factor (VEGF) isoform VEGF165, whose elevated levels are associated with the development of choroidal neovascularization (CNV). This selective inhibition prevents binding to the VEGF receptors and the development of the increased vascular permeability and the CNV associated with neovascular age-related degeneration (AMD). The VEGF Inhibition Study In Ocular Neovascularization (VISION) demonstrated that pegaptanib sodium confers clinically meaningful benefit in the treatment of all angiographic subtypes of neovascular AMD. It also has a favorable safety profile after 1 and 2 years of continuous treatment, and recent data suggest that the agent has a disease-modifying effect. Post hoc analysis of VISION suggests that treatment benefit may be greatest in patients with early lesions, in whom 80% achieved the primary endpoint of &lt;15 letters lost, 47% maintained visual acuity (VA), and 20% gained &ge;15 letters of vision. Similarly, our own clinical experience indicates that pegaptanib sodium achieves better outcomes in early lesions than in established lesions, particularly in patients with previously untreated minimally classic and occult lesions in whom VA improvement and lesion size stabilization has been recorded. Observations indicate that pegaptanib sodium has a slower mode of action than unselective VEGF inhibitors, resulting in an average of 3&ndash;4 injections being required to stabilize VA and lesion size. Pegaptanib sodium has good efficacy and safety profiles and represents a good treatment option for patients with early CNV membranes associated with neovascular AMD.Keywords: vascular endothelial growth factor (VEGF), choroidal neovasularization (CNV), age-related macular degeneration (AMD), pegaptanib sodium, early lesions, visual acuity (VA) Chiara RosinaFerdinando BottoniGiovanni StaurenghiDove Medical PressarticleOphthalmologyRE1-994ENClinical Ophthalmology, Vol 2008, Iss Issue 3, Pp 485-488 (2008)
institution	DOAJ
collection	DOAJ
language	EN
topic	Ophthalmology RE1-994
spellingShingle	Ophthalmology RE1-994 Chiara Rosina Ferdinando Bottoni Giovanni Staurenghi Clinical experience with pegaptanib sodium
description	Chiara Rosina, Ferdinando Bottoni, Giovanni StaurenghiLuigi Sacco Hospital, University of Milano, ItalyAbstract: Pegaptanib sodium (Macugen&reg;) blocks the extracellular vascular endothelial growth factor (VEGF) isoform VEGF165, whose elevated levels are associated with the development of choroidal neovascularization (CNV). This selective inhibition prevents binding to the VEGF receptors and the development of the increased vascular permeability and the CNV associated with neovascular age-related degeneration (AMD). The VEGF Inhibition Study In Ocular Neovascularization (VISION) demonstrated that pegaptanib sodium confers clinically meaningful benefit in the treatment of all angiographic subtypes of neovascular AMD. It also has a favorable safety profile after 1 and 2 years of continuous treatment, and recent data suggest that the agent has a disease-modifying effect. Post hoc analysis of VISION suggests that treatment benefit may be greatest in patients with early lesions, in whom 80% achieved the primary endpoint of &lt;15 letters lost, 47% maintained visual acuity (VA), and 20% gained &ge;15 letters of vision. Similarly, our own clinical experience indicates that pegaptanib sodium achieves better outcomes in early lesions than in established lesions, particularly in patients with previously untreated minimally classic and occult lesions in whom VA improvement and lesion size stabilization has been recorded. Observations indicate that pegaptanib sodium has a slower mode of action than unselective VEGF inhibitors, resulting in an average of 3&ndash;4 injections being required to stabilize VA and lesion size. Pegaptanib sodium has good efficacy and safety profiles and represents a good treatment option for patients with early CNV membranes associated with neovascular AMD.Keywords: vascular endothelial growth factor (VEGF), choroidal neovasularization (CNV), age-related macular degeneration (AMD), pegaptanib sodium, early lesions, visual acuity (VA)
format	article
author	Chiara Rosina Ferdinando Bottoni Giovanni Staurenghi
author_facet	Chiara Rosina Ferdinando Bottoni Giovanni Staurenghi
author_sort	Chiara Rosina
title	Clinical experience with pegaptanib sodium
title_short	Clinical experience with pegaptanib sodium
title_full	Clinical experience with pegaptanib sodium
title_fullStr	Clinical experience with pegaptanib sodium
title_full_unstemmed	Clinical experience with pegaptanib sodium
title_sort	clinical experience with pegaptanib sodium
publisher	Dove Medical Press
publishDate	2008
url	https://doaj.org/article/9a2fea8920124e42b8807847999e82d5
work_keys_str_mv	AT chiararosina clinicalexperiencewithpegaptanibsodium AT ferdinandobottoni clinicalexperiencewithpegaptanibsodium AT giovannistaurenghi clinicalexperiencewithpegaptanibsodium
_version_	1718398378745790464

Clinical experience with pegaptanib sodium

Ejemplares similares